Navigation Links
MRSA vaccine shows promise in mouse study

By combining the four bacterial surface proteins that generate the strongest immune response in mice, researchers at the University of Chicago have created a vaccine that significantly protects immunized animals from multiple disease-causing, drug-resistant strains of Staphylococcus aureus, the most common cause of hospital-acquired infections and a rapidly spreading source of community-associated illness.

The vaccine protected mice against potentially lethal infections with five virulent S. aureus strains, the researchers report in the Nov. 7, 2006, issue of the Proceedings of the National Academy of Sciences, available early online. These strains include USA100, a common cause of hospital-acquired infections, and USA400, a virulent community-associated strain that carries lung-damaging toxins. All five strains were resistant to most of the drugs used to treat S. aureus infections.

"This microbe's ability to acquire the tools it needs to protect itself from the drugs we use to treat it is legendary," said study director Olaf Schneewind, M.D., Ph.D., professor and chairman of microbiology at the University of Chicago, "which is why a vaccine has become such a high priority. One by one, this organism has learned how to evade nearly all of our current antibiotics. So, generating protective immunity against invasive S. aureus has become an important goal."

Previous vaccine attempts using killed or live attenuated bacteria, or selected bacterial subunits, produced, at best, only partial immunity. "For S. aureus vaccines to succeed," said Schneewind, "we need to stimulate an immune response that can recognize the specific cell-surface proteins responsible for virulence and can recognize them from multiple strains."

The researchers turned to a newer technique, known as "reverse vaccinology," recently used to develop candidate vaccines against group A and group B streptococci and group B meningococci. Access to the S. aureus genome
'"/>

Source:University of Chicago Medical Center


Page: 1 2 3

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MRSA vaccine shows promise mouse study

(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March 17, ... here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost & ... - http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies ... compete in several different markets and industries. This ... witnessing an uptrend. Join Frost ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... 2013) For nearly half a century, contact lenses ... delivery that may someday replace eye drops, but achieving ... at Massachusetts Eye and Ear/Harvard Medical School Department of ... Technology are one step closer to an eye drop-free ...
... drives the development of tumours in over one per cent ... the gene CUX1 has been broadly linked to cancer development. ... biological pathway is activated that increases tumour growth. Drugs that ... clinic and are in development thus highlighting a potential new ...
... meets the eye following even a mild traumatic brain injury. ... reported in Nature suggest that the brain,s protective ... Using a newly developed mouse trauma model, senior author Dorian ... and Stroke (NINDS), part of the National Institutes of Health, ...
Cached Biology News:Innovative drug-dispensing contact lens delivers glaucoma medication continuously for a month 2Gene promotes 1 in 100 of tumors 2Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... March 30, 2015 US-Australian drug discovery company, ... subsidiary, CanTx, Inc., and Yale University, on March 27 ... data was presented as an oral presentation by Professor ... School to the 62 nd Annual Scientific Meeting ... San Francisco, CA. In both ...
(Date:3/30/2015)... March 29, 2015 A two-day workshop ... States and plenary talks by four leading photonics researchers ... + Optoelectronics next month in Prague, Czech Republic. ... 17 conferences alongside a two-day exhibition. Sponsored by ... the event will run 13-16 April in the Clarion ...
(Date:3/29/2015)... , March 29, 2015  Caris Life ... in which Caris Molecular Intelligence®, the company,s panomic, ... and differences between several rare and difficult to ... that have the potential to improve patient outcomes. ... B at the Society of Gynecologic Oncology (SGO) ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
... CAMBRIDGE, Mass., Feb. 17 Idenix Pharmaceuticals, Inc. (Nasdaq: ... and development of drugs for the treatment of human viral ... the fourth quarter and year ended December 31, 2008. At ... totaled $46.1 million. Business Highlights , ...
... Relationships Weaken in Many CountriesNEW YORK, Feb. 17 New ... the five major European countries -- the UK, Germany, Spain ... key sales and service activities. Merck takes the top ... UK and Germany. In 2008, Merck and Novartis tied ...
... Inc. (OTC:,SPOM - News), a leading developer of biosensor ... today that it,has appointed Med Tech and Med Care ... US market. , Med Tech ... the healthcare industry and operate with manufacturers,of medical products ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 2Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 3Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 4Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 5Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 6Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 7SPO Medical Appoints New US Sales Rep Groups 2SPO Medical Appoints New US Sales Rep Groups 3
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... This product is designed to deparaffinize and ... formalin fixed paraffin-embedded tissue sections mounted on ... melting the paraffin at the high temperature ... with emulsification of the paraffin by detergent. ...
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
Biology Products: